Drug Industry Balks At Obama's Budget Proposals

Law360, New York (February 13, 2012, 6:34 PM EST) -- The pharmaceutical industry found itself a potential loser Monday in President Barack Obama's proposed 2013 budget, even as U.S. Food and Drug Administration officials vowed to use a $654 million boost in spending — nearly all of it from user fees — to speed reviews of drugs and devices.

The budget proposes several initiatives that the industry strongly opposes: changing Medicare Part D rebates, shortening the exclusivity period for biological drugs and ending “pay for delay” agreements between drug companies.

First, the president's budget would change...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.